Sulfaphenazole

• CAT Number: I003925
• CAS Number: 526-08-9
• Molecular Formula: C15H14N4O2S
• Molecular Weight: 314.4
• Purity: ≥95%
• Target: P450
• Solubility: 10 mM in DMSO
• Storage: 2-8°C
• IUPAC Name: 4-amino-N-(2-phenylpyrazol-3-yl)benzenesulfonamide
• InChI: InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2
• InChIKey: QWCJHSGMANYXCW-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N

Sulfaphenazole (Cat No.: I003925) is a specific inhibitor of CYP2C9, inhibits CYP2C9-mediated linoleic acid atherosclerosis and pro-inflammatory effects (increased oxidative stress and activation of AP-1), and is used for an antibacterial agent. If you need, please contact us in time, and we will reply to you as soon as possible within 24 hours.

Reference

1:Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH.Drug Metab Lett. 2013 Mar;7(1):34-8. PMID: 24329780 Free PMC Article2:Effects of sulfaphenazole after collagenase-induced experimental intracerebral hemorrhage in rats. Hama S, Ishihara Y, Watanabe M, Danjo S, Nakamura Y, Itoh K.Biol Pharm Bull. 2012;35(10):1849-53. PMID: 23037177 Free Article3:Sulfaphenazole attenuates myocardial cell apoptosis accompanied with cardiac ischemia-reperfusion by suppressing the expression of BimEL and Noxa. Ishihara Y, Shimamoto N.J Pharmacol Sci. 2012;119(3):251-9. Epub 2012 Jun 28. PMID: 22785021 Free Article4:A non-acidic sulfaphenazole analog demonstrating high intrinsic clearance and selectivity by canine CYP2C21. Locuson CW, Alfaro JF, Zaya MJ, Billen D, White JA, Jones JP.Drug Metab Lett. 2011 Dec;5(4):253-8. PMID: 22423626 5:Effects of sulfaphenazole derivatives on cardiac ischemia-reperfusion injury: association of cytochrome P450 activity and infarct size. Ishihara Y, Sekine M, Hamaguchi A, Kobayashi Y, Harayama T, Nakazawa M, Shimamoto N.J Pharmacol Sci. 2010;113(4):335-42. Epub 2010 Jul 13. PMID: 20644334 Free Article6:The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. Virdis A, Cetani F, Giannarelli C, Banti C, Ghiadoni L, Ambrogini E, Carrara D, Pinchera A, Taddei S, Bernini G, Marcocci C.J Clin Endocrinol Metab. 2010 Feb;95(2):920-7. doi: 10.1210/jc.2009-1669. Epub 2009 Dec 18. PMID: 20022989 7:Autophagy and protein kinase C are required for cardioprotection by sulfaphenazole. Huang C, Liu W, Perry CN, Yitzhaki S, Lee Y, Yuan H, Tsukada YT, Hamacher-Brady A, Mentzer RM Jr, Gottlieb RA.Am J Physiol Heart Circ Physiol. 2010 Feb;298(2):H570-9. doi: 10.1152/ajpheart.00716.2009. Epub 2009 Dec 11. PMID: 20008275 Free PMC Article8:Letter by Brown and Pretorius regarding article, /effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients/. Brown NJ, Pretorius M.Circulation. 2009 Nov 10;120(19):e159; author reply e160. doi: 10.1161/CIRCULATIONAHA.109.874743. No abstract available. PMID: 19901200 Free Article9:A sulfaphenazole-sensitive EDHF opposes platelet-endothelium interactions in vitro and in the hamster microcirculation in vivo. Krötz F, Hellwig N, Bürkle MA, Lehrer S, Riexinger T, Mannell H, Sohn HY, Klauss V, Pohl U.Cardiovasc Res. 2010 Feb 1;85(3):542-50. doi: 10.1093/cvr/cvp301. Epub 2009 Aug 28. PMID: 19717402 10:Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. Giannarelli C, Virdis A, De Negri F, Magagna A, Duranti E, Salvetti A, Taddei S.Circulation. 2009 Mar 31;119(12):1625-33. doi: 10.1161/CIRCULATIONAHA.108.782482. Epub 2009 Mar 16. Erratum in: Circulation. 2009 Nov 10;120(19):e161. Dosage error in article text. PMID: 19289643 Free Article